<p><strong>Hims &amp; Hers Health Inc</strong> (NYSE: HIMS) 的股票在周二上涨，因为投资者继续对新任首席医疗领导的任命作出反应，并对医疗保健股票的整体积极走势表示乐观。以下是投资者需要了解的内容 need to know。</p>
<ul>
<li>Hims &amp; Hers Health 的股票今天飙升至新高。是什么推动了 HIMS 的势头？</li>
</ul>
<h2>HIMS 股票：关键水平和动量指标</h2>
<p>从趋势的角度来看，HIMS 的表现像是一次 “修复” 反弹：它的交易价格高于其 20 日简单移动平均线（SMA）($25.39)、50 日 SMA ($24.96) 和 100 日 SMA ($23.61)，但仍低于其 200 日 SMA ($33.89) 17.8%，这使得长期偏向保持谨慎。这种分裂通常出现在股票建立基础但尚未证明能够维持完全趋势反转时。</p>
<p>MACD 目前是更清晰的动量指标：它在信号线之上，直方图为正，这表明下行压力相较于之前的下跌正在减轻。通俗来说，MACD 比较快速和缓慢的趋势指标，位于信号线之上通常意味着动量在改善而不是恶化。</p>
<p>更大的背景是 2025 年 12 月形成的死亡交叉（50 日 SMA 低于 200 日 SMA），这就是为什么多头通常希望看到后续走势开始重新夺回长期平均线。在水平图上，$30.50 是一个附近的区域，如果买家不继续施压，反弹可能会受限。</p>
<ul>
<li><strong>关键阻力</strong>：$30.50 — 一个附近的水平，反弹可能会停滞，位于当前价格之上，接近 200 日指数移动平均线（EMA）区间 ($30.55)</li>
</ul>
<h2>Hims &amp; Hers Health 股票的驱动因素是什么？</h2>
<p>Hims &amp; Hers 上周任命 <strong>Anant Vinjamoori</strong> 为首席医疗官，强调了他在长寿医学和预防医疗方面的背景，并突出了拥有超过 100 年综合经验的医疗领导团队，涵盖减肥、性健康、激素健康、心理健康、皮肤科和初级护理等领域。</p>
<p>Vinjamoori 将机会框架围绕 “主动、科学驱动的护理” 需求，这一信息与 Hims &amp; Hers 推动从偶发治疗扩展到长期客户关系的目标相契合。</p>
<h2>Hims &amp; Hers Health 是什么？</h2>
<p>Hims &amp; Hers 于 2017 年推出，是一个远程医疗平台，连接患者和医疗提供者，涉及勃起功能障碍、脱发、皮肤护理、心理健康和减肥等领域。它销售通用药物、品牌药物和复方处方药，以及非处方药、化妆品和补充剂。</p>
<p>该平台拥有超过 200 万订阅者，并在所有 50 个州以及英国等某些欧洲市场运营，支持提供者网络、电子病历、云药房履行和个性化工具。由于 Hims 不接受保险，依赖直接客户支付，因此医疗领导和临床信誉对信任、客户留存和扩展到主动护理类别至关重要。</p>
<h2>周二 HIMS 股票价格走势</h2>
<p><strong>HIMS 股票价格活动：</strong> 根据 Benzinga Pro 数据，Hims &amp; Hers Health 的股票在周二发布时上涨 1.91%，报 $27.69。</p>
<p><strong>另请阅读：</strong>
<strong>今日股市：标准普尔 500 指数、道琼斯期货因以色列、伊朗停火而上涨——Amplitech Group、Vail Resorts、Mission Produce 备受关注</strong></p>
<p><em>图片来源：Shutterstock</em></p>

HIMS

HIMY

2 倍做多 HIMS ETF - Defiance

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）股价上涨 1.91%，至 27.69 美元，主要受到 Anant Vinjamoori 被任命为首席医疗官以及医疗股票积极情绪的推动。从技术上看，该股票显示出改善的动能，MACD 信号向好，但仍低于其 200 日简单移动平均线，面临 30.50 美元的阻力</p>

<p><strong>Hims &amp; Hers Health Inc</strong> (NYSE: HIMS) shares are trading higher on Tuesday as investors continue to react to a new chief medical leadership appointment and lean into a generally constructive tape for healthcare stocks. Here’s what investors need to know.</p>
<div class="lb-trans"><p><strong>Hims &amp; Hers Health Inc</strong> (NYSE: HIMS) 的股票在周二上涨，因为投资者继续对新任首席医疗领导的任命作出反应，并对医疗保健股票的整体积极走势表示乐观。以下是投资者需要了解的内容 need to know。</p>
</div><ul>
<li>Hims &amp; Hers Health stock is surging to new heights today. What’s fueling HIMS momentum?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 的股票今天飙升至新高。是什么推动了 HIMS 的势头？</li>
</ul>
</div><h2>HIMS Stock: Key Levels And Momentum Indicators</h2>
<div class="lb-trans"><h2>HIMS 股票：关键水平和动量指标</h2>
</div><p>From a trend perspective, HIMS is acting like a &#34;repair&#34; rally: it's trading above its 20-day SMA ($25.39), 50-day SMA ($24.96), and 100-day SMA ($23.61), but it's still trading 17.8% below its 200-day SMA ($33.89), which keeps the longer-term bias cautious. That split often shows up when a stock is building a base but hasn't proven it can sustain a full trend reversal.</p>
<div class="lb-trans"><p>从趋势的角度来看，HIMS 的表现像是一次 “修复” 反弹：它的交易价格高于其 20 日简单移动平均线（SMA）($25.39)、50 日 SMA ($24.96) 和 100 日 SMA ($23.61)，但仍低于其 200 日 SMA ($33.89) 17.8%，这使得长期偏向保持谨慎。这种分裂通常出现在股票建立基础但尚未证明能够维持完全趋势反转时。</p>
</div><p>MACD is the cleaner momentum read right now: it's above its signal line and the histogram is positive, which suggests downside pressure is easing versus the prior downswing. In plain English, MACD compares faster and slower trend measures, and being above the signal line typically means momentum is improving rather than deteriorating.</p>
<div class="lb-trans"><p>MACD 目前是更清晰的动量指标：它在信号线之上，直方图为正，这表明下行压力相较于之前的下跌正在减轻。通俗来说，MACD 比较快速和缓慢的趋势指标，位于信号线之上通常意味着动量在改善而不是恶化。</p>
</div><p>The bigger-picture overhang is the death cross that set up in December 2025 (the 50-day SMA below the 200-day SMA), which is why bulls usually want to see follow-through that starts reclaiming longer-term averages. On the level-to-level map, $30.50 is the nearby area that can cap rebounds if buyers don't keep pressing.</p>
<div class="lb-trans"><p>更大的背景是 2025 年 12 月形成的死亡交叉（50 日 SMA 低于 200 日 SMA），这就是为什么多头通常希望看到后续走势开始重新夺回长期平均线。在水平图上，$30.50 是一个附近的区域，如果买家不继续施压，反弹可能会受限。</p>
</div><ul>
<li><strong>Key Resistance</strong>: $30.50 — a nearby level where rebounds can stall, sitting just above current price and near the 200-day EMA zone ($30.55)</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>关键阻力</strong>：$30.50 — 一个附近的水平，反弹可能会停滞，位于当前价格之上，接近 200 日指数移动平均线（EMA）区间 ($30.55)</li>
</ul>
</div><h2>What Is Driving Hims &amp; Hers Health’s Stock?</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票的驱动因素是什么？</h2>
</div><p>Hims &amp; Hers last week named <strong>Anant Vinjamoori</strong> as chief medical officer, pointing to his background in longevity medicine and preventive healthcare, and highlighting a medical leadership bench with more than 100 years of combined experience across weight loss, sexual health, hormone health, mental health, dermatology and primary care.</p>
<div class="lb-trans"><p>Hims &amp; Hers 上周任命 <strong>Anant Vinjamoori</strong> 为首席医疗官，强调了他在长寿医学和预防医疗方面的背景，并突出了拥有超过 100 年综合经验的医疗领导团队，涵盖减肥、性健康、激素健康、心理健康、皮肤科和初级护理等领域。</p>
</div><p>Vinjamoori framed the opportunity around demand for &#34;proactive, science-driven care,&#34; a message that fits Hims &amp; Hers' push to broaden beyond episodic treatment into longer-duration customer relationships.</p>
<div class="lb-trans"><p>Vinjamoori 将机会框架围绕 “主动、科学驱动的护理” 需求，这一信息与 Hims &amp; Hers 推动从偶发治疗扩展到长期客户关系的目标相契合。</p>
</div><h2>What Is Hims &amp; Hers Health?</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 是什么？</h2>
</div><p>Hims &amp; Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers for areas like erectile dysfunction, hair loss, skin care, mental health and weight loss. It sells generic, branded, and compounded prescription drugs along with over-the-counter medicines, cosmetics and supplements.</p>
<div class="lb-trans"><p>Hims &amp; Hers 于 2017 年推出，是一个远程医疗平台，连接患者和医疗提供者，涉及勃起功能障碍、脱发、皮肤护理、心理健康和减肥等领域。它销售通用药物、品牌药物和复方处方药，以及非处方药、化妆品和补充剂。</p>
</div><p>The platform has more than 2 million subscribers and operates in all 50 states plus certain European markets like the UK, supported by provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization tools. Because Hims doesn't take insurance and relies on direct customer payments, medical leadership and clinical credibility can matter for trust, retention, and expanding into proactive-care categories.</p>
<div class="lb-trans"><p>该平台拥有超过 200 万订阅者，并在所有 50 个州以及英国等某些欧洲市场运营，支持提供者网络、电子病历、云药房履行和个性化工具。由于 Hims 不接受保险，依赖直接客户支付，因此医疗领导和临床信誉对信任、客户留存和扩展到主动护理类别至关重要。</p>
</div><h2>HIMS Stock Price Movement On Tuesday</h2>
<div class="lb-trans"><h2>周二 HIMS 股票价格走势</h2>
</div><p><strong>HIMS Stock Price Activity:</strong> Hims &amp; Hers Health shares were up 1.91% at $27.69 at the time of publication on Tuesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>HIMS 股票价格活动：</strong> 根据 Benzinga Pro 数据，Hims &amp; Hers Health 的股票在周二发布时上涨 1.91%，报 $27.69。</p>
</div><p><strong>Read Also:</strong>
<strong>Stock Market Today: S&amp;P 500, Dow Jones Futures Gain Over Israel, Iran Ceasefire—Amplitech Group, Vail Resorts, Mission Produce In Focus</strong></p>
<div class="lb-trans"><p><strong>另请阅读：</strong>
<strong>今日股市：标准普尔 500 指数、道琼斯期货因以色列、伊朗停火而上涨——Amplitech Group、Vail Resorts、Mission Produce 备受关注</strong></p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：Shutterstock</em></p>
</div>

Hims & Hers 股票小幅上涨：究竟发生了什么？